Investigation of AllergyCut therapeutic effect of Allergic Rhinitis patients
Phase 2
Completed
- Conditions
- Rhinitis Allergy.Allergic rhinitis, unspecified
- Registration Number
- IRCT20170705034915N2
- Lead Sponsor
- MIM Daroo Pharmaceutical Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Patients with Rhinitis after diagnosis by an immunologist or ENT physician
Male and female patient who has symptoms of allergic rhinitis at least one month per year.
A patient aged over 16 years old up to 60 years old who has the opportunity to complete the day care and has an effective relationship with the counselor.
A patient who does not have allergy to herbal medicines.
Exclusion Criteria
Patient with rhinitis without diagnosis of immunological basis.
Patients who do not want to start or continue treatment are not eligible for study.
Patients who provide incomplete data to the counselor.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduced Indicators Related to Rhinitis in Patients Consuming the Drugs. Timepoint: Drug intakes for 60 to 120 days. Method of measurement: Study of allergy-related rhinitis allergy indexes under the supervision of an immunologist.
- Secondary Outcome Measures
Name Time Method